

# ForPatients

*by Roche*

Colorectal Cancer (CRC) Non-Small Cell Lung Cancer (NSCLC) Pancreatic  
Adenocarcinoma Ovarian Neoplasms Renal Cell Carcinoma

## Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

**Trial Status**  
Terminated

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT05769959 BP44068

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).

**Hoffmann-La Roche**  
Sponsor

**Phase 1/Phase 2**  
Phase

**NCT05769959 BP44068**  
Trial Identifiers

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No